CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
cisplatin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01076231
NCT01076231Phase 2Completed

Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC

Abramson Cancer Center at Penn Medicine·interventional·Posted Feb 26, 2010·Updated May 17, 2021

In Brief

A Phase 2 clinical trial evaluating proton beam radiation therapy, cisplatin, and 2 other interventions for Stage IIIA Non-small Cell Lung Cancer. Completed, enrolled 34 participants across 1 site.

Detailed Summary

RATIONALE: Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with non-small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving proton beam radiation therapy together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of proton beam radiation therapy when given together with cisplatin and etoposide and to see how well it works in treating patients with stage III non-small cell lung cancer that can be removed by surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2010
Enrollment StartJan 1, 2010
Primary CompletionDec 1, 2016
Study CompletionMay 24, 2018
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 16.3 years ago

Interventions

proton beam radiation therapyradiation

cisplatindrug

Given IV

etoposidedrug

Given IV

therapeutic conventional surgeryprocedure